BioMark Diagnostics Inc. announced Update on Company Outlook for 2022. Consistent with BioMark's commercialization strategies of its liquid biopsy platform for the early detection of hard to detect and treat cancers, the Company will accelerate certain initiatives in 2022, including: A retrospective analysis of 1,200 patient samples to not only validate the performance of the metabolite biomarker panel for early lung cancer detection but also evaluate its ability to differentiate lung cancer from other medical conditions. BioMark is working with collaborators at the University of Alberta's Metabolomics Innovation Centre on this project and expects to see results in the second half of 2022.

Starting early in 2022, BioMark will initiate its second clinical study which involves the prospective validation of the lung cancer metabolite biomarkers in combination with genomic and radiomic biomarkers. Investigators in eight Quebec hospitals will be recruiting 4,000 at risk individual to validate the multiomics approach, as part of a collaboration involving AstraZeneca, Pfizer Canada, and the Quebec Heart and Lung Institute. BioMark is currently focused on bringing its lab-developed test (LDT) and detection solution to commercialization standards and hopes to commence distribution once the above-mentioned clinical trials are completed and regulatory approval is obtained.

Meanwhile, the firm also has plans to expand international collaborations to implement its liquid biopsy test in lung cancer screening program from leading US Medical Centers and European agencies.